Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

  • STATUS
    Recruiting
  • End date
    Jun 13, 2023
  • participants needed
    100
  • sponsor
    Versailles Hospital
Updated on 13 August 2020

Summary

Patients will be randomized in phase II trials to continue on the same TKI versus one of the alternative treatment approaches. If a patient is not eligible for one of the treatments, he (she) will be randomized between the options for which he (she) is eligible.

The trial will start with current available treatment options (experimental arms). New available treatment options may be open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib.

For all options the treatment duration is for a minimum of 12 months and will be continued in the absence of adverse events following investigator decision. Each therapeutic option will be detailed in term of combination modalities, dose, dose adaptation, specific warnings, specific exclusion and inclusion criteria. The decision to introduce a new option will depend on the general pace of recruitment and on the assessment of the potential efficacy and safety of the new treatment, and will be implemented after scientific review by a protocol amendment.

Primary objective:

  1. To select molecules in combination or sequentially with imatinib, nilotinib, dasatinib, bosutinib or ponatinib potentially able to produce a 25% increase in the Cumulative Incidence of MR4.5 as compare to control.

Secondary objectives:

  1. To determine the safety of selected therapies
  2. To determine the rate of MR4 by 12, 24, 36, 48 months in experimental and control arms
  3. To determine the rates of MR4.5 by 24, 36, 48 months in experimental and control arms
  4. To determine the rate of undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12, 24, 36, 48 months in experimental and control arms
  5. To estimate treatment free remission (TFR) in patients eligible for discontinuation studies
  6. To investigate the relationship between biological activity and the clinical efficacy of the selected therapies
  7. To assess the effects of the treatments on the number and clonogenicity of CML stem cells and other biological markers of interest
  8. To estimate duration of response, progression-free survival, event free survival and overall survival.

Description

Patients will be randomised to continue on TKI (same daily dose) versus one of the alternative novel treatment approaches. If a patient is not eligible for one of the treatments, he can be randomised for the options for which he is eligible. All treatment options may be open at all times. Investigators must specify before randomization for which treatment option they want their patient be included and randomized.

Perspectives New treatment options will be introduced over time. The decision to introduce a new option will depend on the general pace of recruitment and the assessment of the potential efficacy and safety of the new treatment in this patient population, and will be implemented after scientific review by a protocol amendment.

The available treatment arms are:

  1. TKI alone same daily dose (control arm)
  2. TKI in combination with pioglitazone
  3. TKI in combination with Avelumab (anti-PD-L1 antibody)

Planned treatment arms for the future may be :

  1. TKI in combination with pegylated interferon
  2. TKI in combination with arsenic trioxide
  3. TKI in combination with Homoharringtonine

Protocol plan:

  1. Control arm (Imatinib, nilotinib, dasatinib, bosutinib or ponatinib):

Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months

2. Pioglitazone arm

  • TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
  • PIOGLITAZONE (Actos):

30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.

  • After 12 Months :

Continue TKI at the same daily dose and STOP pioglitazone.

3. AVELUMAB arm

  • TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
  • AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
  • After 12 Months :Continue TKI at the same daily dose. 4. Other experimental arm TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
  • Arsenic trioxide : to be determined after amendment
  • Pegylated Interferon : to be determined after amendment
  • Homoharringtonine : to be determined after amendment
  • Drug X
  • Drug Y

Details
Treatment Avelumab, pioglitazone
Clinical Study IdentifierNCT02767063
SponsorVersailles Hospital
Last Modified on13 August 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have chronic phase chronic myelogenous leukemia?
Patient aged 18y or more
Signed informed consent
Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL1 transcript positivity at diagnosis
Treatment with imatinib, nilotinib, dasatinib or bosutinib for more than 2 years overall
No switch between tyrosine kinase inhibitors within the last 3 months
No dose modification within the last 3 months
Complete cytogenetic response or BCR-ABL1IS 1%
Detectable BCR-ABL1 with BCR-ABL1IS > 0.0032% (less than MR4.5)
ECOG grade 0 to 2
ASAT and ALAT 2.5 N
Bilirubin in serum 2.5 N
Men and Women of childbearing potential must be using an adequate method of contraception
These specific inclusion criteria will apply for the Avelumab arm in addition
to the common criteria
Hematologic
Absolute neutrophil count (ANC) 1.5 109/L
Platelet count 100 109/L
Hemoglobin 9 g/dL. (may have been transfused)
Hepatic
Total bilirubin level 1.5 the upper limit of normal (ULN) range
Renal: Estimated creatinine clearance 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
Pregnancy test: Negative serum or urine pregnancy test at screening for women of childbearing potential
Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last Avelumab treatment administration if the risk of conception exists

Exclusion Criteria

Pregnant or lactating women
Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment
Prior history of hematopoietic stem cell transplantation (autologous or allogenic)
Cardiovascular disease
Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure
Myocardial infarction within the previous 6 months
Symptomatic cardiac arrhythmia requiring treatment
Grade III or IV fluid retention
Known BCR-ABL kinase domain mutation
CML patient not in chronic phase at diagnosis
Individuals with an active malignancy
Known HIV-positivity
These specific exclusion criteria will apply for the pioglitazone arm in
addition to the common criteria
Known osteoporosis with curative therapy (prophylactic therapy is not an exclusion criteria)
Patient requiring anti-diabetic medication
These specific exclusion criteria will apply for the Avelumab arm in addition
to the common
criteria
IMMUNOSUPRESSANTS: Current use of immunosuppressive medication, EXCEPT for the
following
intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection)
Systemic corticosteroids at physiologic doses 10 mg/day of prednisone or equivalent
Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypoor hyperthyroid diseases not requiring immunosuppressive treatment are eligible
ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation
INFECTIONS: Active infection requiring systemic therapy
HIV/AIDS: Known history of testing positive for HIV or known acquired immunodeficiency syndrome
HEPATITIS: Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)
VACCINATION: Vaccination within 4 weeks of the first dose of Avelumab and while on trials is prohibited except for administration of inactivated vaccines
HYPERSENSITIIVTY TO STUDY DRUG: Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions tomonoclonal antibodies (NCI CTCAE v4.03 Grade 3)
CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure ( New York Heart Association Classification Class II), or serious cardiac arrhythmia equiring medication
OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI CTCAE
4.03 Grade > 1); however, alopecia, sensory neuropathy Grade 2, or other Grade 2 not constituting a safety risk based on investigator's judgment are acceptable
Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet